【24h】

Minimally Clinically Important Difference (MCID) Is a Low Bar

机译:最低临床重要性差异 (MCID) 是一个低门槛

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

? 2022 Arthroscopy Association of North AmericaPatients don't care about “statistical” significance. Patient-centered outcome measures focus on “clinical” significance and include minimal clinically important difference (MCID), patient acceptable symptomatic state (PASS), substantial clinical benefit (SCB), and maximal outcome improvement (MOI). “Minimal” is a low bar. MCID neither addresses whether patients are satisfied nor whether they have derived a substantial benefit. MCID is commonly reported allowing comparison between studies, and MCID can be calculated retrospectively, so reporting MCID is acceptable. However, we also need to report PASS, SCB, and, in unique patients like high-level athletes, we may also need to report MOI to adjust for high pretreatment scores and a ceiling effect. Finally, threshold scores are patient-level metrics and must be reported as percentage of patients who meet the threshold, not reported as to whether, as a group, the mean score for the cohort meets the threshold or not (which is a common error).
机译:?2022 年北美关节镜协会患者不关心“统计学”意义。以患者为中心的结果测量侧重于“临床”意义,包括最小临床重要差异 (MCID)、患者可接受症状状态 (PASS)、实质性临床获益 (SCB) 和最大结果改善 (MOI)。“最小”是一个低门槛。MCID既没有解决患者是否满意的问题,也没有解决他们是否获得了实质性的益处。MCID通常用于报告,以便进行研究之间的比较,并且MCID可以回顾性计算,因此报告MCID是可以接受的。然而,我们还需要报告 PASS、SCB,并且在高水平运动员等特殊患者中,我们可能还需要报告 MOI 以调整高治疗前评分和上限效应。最后,阈值分数是患者水平的指标,必须报告为达到阈值的患者百分比,而不是报告队列的平均分数是否达到阈值(这是一个常见错误)。
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号